Effect of colibacillosis or coccidiosis on expression of breast cancer resistance protein in small intestine and liver of chickens

2013 ◽  
Vol 37 (1) ◽  
pp. 53-58 ◽  
Author(s):  
L. Su ◽  
L. Dong ◽  
S. Bughio ◽  
M. Guo ◽  
L. Wang
Keyword(s):  
Breast Cancer ◽  
Small Intestine ◽  
Breast Cancer Resistance Protein ◽  
Cancer Resistance ◽  
Resistance Protein

PDZK1 Regulates Breast Cancer Resistance Protein in Small Intestine

2011 ◽  
Vol 39 (11) ◽  
pp. 2148-2154 ◽  
Author(s):  
Takuya Shimizu ◽  
Tomoko Sugiura ◽  
Tomohiko Wakayama ◽  
Ai Kijima ◽  
Noritaka Nakamichi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Small Intestine ◽  
Breast Cancer Resistance Protein ◽  
Cancer Resistance ◽  
Resistance Protein

scholarly journals Differential Effects of Chrysin on Nitrofurantoin Pharmacokinetics Mediated by Intestinal Breast Cancer Resistance Protein in Rats and Mice

2009 ◽  
Vol 12 (2) ◽  
pp. 150 ◽  
Author(s):  
Atsushi Kawase ◽  
Yukako Matsumoto ◽  
Motoshi Hadano ◽  
Yui Ishii ◽  
Masahiro Iwaki
Keyword(s):  
Breast Cancer ◽  
Small Intestine ◽  
Breast Cancer Resistance Protein ◽  
Plasma Concentrations ◽  
Mrna Levels ◽  
Cancer Resistance ◽  
Glycoprotein P ◽  
Metabolizing Enzymes ◽  
Resistance Protein ◽  
Rats And Mice

PURPOSE: The activities of breast cancer resistance protein (Bcrp/ABCG2) as well as P-glycoprotein (P-gp) and drug-metabolizing enzymes can be inhibited by several flavonoids or drugs in rats. However, the species, gender and regional differences of effects of flavonoids on Bcrp/ABCG2 in rats and mice remain unclear, although Bcrp, like P-gp, is also important in controlling drug absorption and disposition. METHODS: We used chrysin as a model flavonoid because it possesses anti-inflammatory and antioxidative properties and is used as a dietary supplement. We examined the pharmacokinetics of nitrofurantoin, a specific Bcrp substrate, in rats and mice treated with chrysin. Bcrp mRNA levels were measured in liver, kidney, duodenum, jejunum and ileum in rats and mice. RESULTS: Plasma concentrations of nitrofurantoin were increased in rats, but not mice, treated with oral chrysin, compared with untreated controls. Intraperitoneal injection of chrysin into rats or mice had little effect on the elimination of nitrofurantoin, compared with untreated animals. CONCLUSIONS: These results suggest that chrysin-nitrofurantoin interactions occur in the small intestine in rats, but not in mice, possibly due to the higher levels of Bcrp expression in the small intestine in rats, compared with those in mice.

Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer

2020 ◽  
Vol 21 ◽  
Author(s):  
Sonali Mehendale-Munj
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Resistance Protein ◽  
Protein A ◽  
The Body ◽  
Cancer Therapies ◽  
Cancer Resistance ◽  
Lung Cancers ◽  
Resistance Protein ◽  
Atp Regulation ◽  
Treatment Procedures

: Breast Cancer Resistance Protein (BCRP) is an efflux transporter responsible for causing multidrug re-sistance(MDR). It is known to expel many potent antineoplastic drugs, owing to its efflux function. Efflux of chemothera-peutics because of BCRP develops resistance to manydrugs, leading to failure in cancer treatment. BCRP plays an important role in physiology by protecting the organism from xenobiotics and other toxins. It is a half-transporter affiliated to theATP-binding cassette (ABC) superfamily of transporters, encoded by the gene ABCG2 and functions in response to adenosine triphosphate (ATP). Regulation of BCRP expression is critically controlled at molecular levels which help in maintaining the balance of xenobiotics and nutrients inside the body. Expression of BCRP can be found in brain, liver, lung cancers and acute myeloid leukemia (AML). Moreover, it is also expressed at high levels in stem cells and many cell lines. This frequent expression of BCRP has an impact on the treatment procedures and if not scrutinized may lead to failure of many cancer therapies.

Sign in / Sign up

Export Citation Format

Share Document